Emerging data from pivotal clinical trials also indicate that IL-23 inhibitors may offer a promising therapeutic option for PPP, although the current studies are limited by small sample sizes and short follow-up durations [16,17]. The gene discussed is IL23A; the disease is palmoplantar pustulosis.